- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06104150
Erythrocyte Transport of Lactate During Exercise (TELE Project) (TELE)
Transporte Eritrocitario de Lactato en Ejercicio
The goals of this clinical trial are:
- to study lactate kinetic between plasma and erythrocytes during an intervallic exercise and its subsequent recovery, considering the blood pH, the genotype for the T1470A polymorphism of the SLC16A1 gene (rs1049434), and the amount of MCT1 in erythrocytes membrane;
- to analyze the levels of MCT1 in the erythrocytes membrane according to training status and genotype for the T1470A polymorphism of SLC16A1 (rs1049434).
For this, the project will have two phases:
- In phase I, trained participants will perform one maximal incremental test and one intervallic submaximal test with a final active recovery.
- Phase II, levels of the MCT1 protein in the erythrocyte membrane will be quantified from trained and sedentary participants.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction
Lactate is the end product of glycolysis and has the capacity to be transported from one cell to another, performing numerous functions. This transport is mainly through several monocarboxylate transporters (MCT). The most predominant is MCT1, which transfers lactate bidirectionally depending on the lactate concentration and pH on each side of the membrane. MCT1 is ubiquitous, being present in most human tissues like the erythrocyte membrane, indicating that these cells are capable of carrying lactate throughout the bloodstream. Some studies have described lactate kinetics between the different blood compartments (erythrocyte-plasma) during incremental and steady-state exercises, but not during intermittent exercise and/or recovery after exercise. Moreover, several studies have observed that the function of MCT1 is conditioned by the presence of a genetic variant: the T1470A polymorphism (rs1049434), which involves a substitution of aspartic acid for glutamic acid at position 490 of the protein. Data suggest that an AA (Glu/Glu) genotype for this single nucleotide polymorphism (or SNP) leads to a higher lactate transport capacity than the TT (Arg/Arg) profile. However, no study has analyzed if this SNP directly affects erythrocyte MCT1 function or content Therefore, the two general objectives of this clinical trial are:
- to study lactate kinetic between plasma and erythrocytes during an intervallic exercise and its subsequent recovery, considering the blood pH, the genotype for the T1470A polymorphism of the SLC16A1 gene (rs1049434), and the amount of MCT1 in erythrocytes membrane;
- to analyze the levels of MCT1 in the erythrocytes membrane according to training status and genotype for the T1470A polymorphism of SLC16A1 (rs1049434).
Procedures
The study will be divided into two phases, each of which will be primarily oriented toward achieving one of two general objectives:
- Phase I: Focused primarily on the study of lactate kinetics between blood compartments during exercise.
- Phase II: Focused primarily on the analysis of the amount of MCT1 in the erythrocyte membrane.
For both phases, volunteers will be informed and sign an informed consent form before a blood sample is taken for genotyping. Once the genotype is known, only those participants with AA or TT genotype will be selected.
The tests that will be performed throughout Phase I will be the following:
- Once participants with the genotypes AA and TT are selected, they will perform a step incremental test until exhaustion to determine the first and second lactate threshold. These thresholds will be determined by measuring lactate concentration from capillary blood samples from the earlobe.
- Finally, an intervallic exercise protocol will be performed starting with 1 min rest followed by a 5 min warm up at an intensity equal to 80% of the first lactate threshold. This is followed by 4 sets of 1 min 30 sec at an intensity 20% above the second lactate threshold, with recovery intervals of 5 min at 80% of the first lactate threshold. After the 4 sets, a final recovery of 20 min at 80% of the first lactate threshold will be performed. During this test, capillary blood samples from the earlobe and venous blood samples from the forearm will be analyzed for lactate concentration.
The procedure for the Phase II will be the following:
- Once participants with the genotype AA and TT are selected, venous blood will be extracted from their forearm at rest.
- Physical activity levels from all the participants will be quantified using the International Physical Activity Questionnaire (IPAQ).
- Analysis of the erythrocyte MCT1 protein content by flow cytometry will be performed from the venous blood samples.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rocío Cupeiro, PhD
- Phone Number: +34910677990
- Email: rocio.cupeiro@upm.es
Study Locations
-
-
-
Madrid, Spain, 28040
- Recruiting
- Laboratorio de Fisiología del Esfuerzo. Facultad de Ciencias de la Actividad Física y del Deporte (INEF). Universidad Politécnica de Madrid
-
Contact:
- Rocío Cupeiro, PhD
- Phone Number: +34910677990
- Email: rocio.cupeiro@upm.es
-
Principal Investigator:
- Rocío Cupeiro, PhD
-
Sub-Investigator:
- Jose A Benítez-Muñoz, MS
-
Sub-Investigator:
- Miguel A Rojo-Tirado, PhD
-
Contact:
- Ildefonso Fernández
- Phone Number: +34910677866
- Email: laboratorio.fisiologia.inef@upm.es
-
Sub-Investigator:
- Jacobo Á Rubio, PhD
-
Sub-Investigator:
- Pedro J Benito, PhD
-
-
Cantabria
-
Santander, Cantabria, Spain, 39011
- Recruiting
- Laboratorio de Pediatría. School of Medicine. Univesidad de Cantabria
-
Contact:
- Teresa Amigo
- Email: teresa.amigo@unican.es
-
Principal Investigator:
- Domingo González-Lamuño, PhD
-
Sub-Investigator:
- Teresa Amigo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- BMI between 18 and 25 kg/m2
- Not smoker
- In the case of trained participants: training at least 5 hours/week, of which at least 3 must be aerobic/anaerobic endurance training. Presentation of a medical certificate attesting to their medical fitness (capability) to perform intense physical exercise.
- In the case of sedentary participants, less than 1 day of training per week or less than 2 hours of structured exercise per week.
Exclusion Criteria:
- Presenting any pathology that could impede the correct performance of the tests, or could influence the main study variables.
- In the case of the female sample, having irregular menstrual cycles, oligomenorrhea or amenorrhea.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervallic submaximal test
Intervallic exercise test
|
Intervallic submáximal exercise test on a cycle ergometer: 5 min warm-up at 80% of First Lactate Threshold (LT1), and subsequent sets of 1.5 min at 20% above the Second Lactate Threshold (LT2) alternated with recoveries of 5 min at 80% of LT1, ending with a 20 min recovery at 80% of LT1.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma-Erythrocyte lactate difference
Time Frame: Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years
|
Difference between lactate concentration inside the erythrocytes and lactate concentration in plasma, expressed in mMol/L (Millimoles Per Liter), from venous blood extracted during the intervallic test from the antecubital vein.
|
Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years
|
Level of Monocarboxylate Transporter 1 in erythrocytes membrane
Time Frame: Through study completion, average of 5 years, an average of 2 months per participant
|
Protein abundance of the monocarboxylate transporter 1 in erythrocyte membranes.
It is measured using flow cytometry, from venous blood extracted from the forearm in rest state.
|
Through study completion, average of 5 years, an average of 2 months per participant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Erythrocyte lactate concentration
Time Frame: Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years
|
Lactate concentration inside the erythrocytes, expressed in mMol/L (Millimoles Per Liter), measured in erythrocytes extracted from processed venous blood. Lactate concentration is measured in the supernatant obtained after the lysis and centrifugation of the solid part of the blood (mainly erythrocytes), separated by centrifugation. Venous blood samples are extracted during the intervallic test from the antecubital vein. |
Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years
|
Plasma lactate concentration
Time Frame: Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years
|
Lactate concentration, expressed in mMol/L (Millimoles Per Liter), measured in the plasma of centrifugated venous blood, using a lactate analyzer. Lactate concentration is measured in the plasma obtained from venous blood extracted during the intervallic test from the antecubital vein. |
Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years
|
Blood lactate concentration
Time Frame: Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years
|
Lactate concentration, expressed in mMol/L (Millimoles Per Liter), measured from whole venous blood extracted during the intervallic test from the antecubital vein.
|
Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years
|
Blood pH
Time Frame: Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years
|
Level of blood pH measured in venous blood extracted during the intervallic test from the antecubital vein.
|
Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Genotype for the rs1049434 polymorphism of the SLC16A1 (MCT1) gene
Time Frame: Through sample recruitment, average of 5 years, an average of 1 month per participant
|
Genotype for the Asp490Glu (T1470A) (rs1049434) polymorphism of the SLC16A1 (MCT1) gene, resulting in one of the following three profiles: TT (Arg/Arg), TA (Arg/Glu) or AA (Glu/Glu)
|
Through sample recruitment, average of 5 years, an average of 1 month per participant
|
Physical Activity level
Time Frame: Through sample recruitment, average of 5 years, an average of 1 month per participant
|
The IPAQ self-reported questionnaire will be used to quantify physical activity levels.
|
Through sample recruitment, average of 5 years, an average of 1 month per participant
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rocío Cupeiro, PhD, Universidad Politécnica de Madrid.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PINV-18-ENW9ML-92-B2287R
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Energy Metabolism
-
Wageningen UniversityTNO; Gelderse Vallei Hospital; Bonumose, Inc.RecruitingEnergy Intake | Energy MetabolismNetherlands
-
Institut National de Recherche pour l'Agriculture...Centre de Recherche en Nutrition Humaine Rhone-Alpe; Centre de Recherche en...CompletedEnergy Expenditure | Computer Simulation | Energy MetabolismFrance
-
Ori Diagnostic Instruments LLCSuspendedBody Composition | Energy Expenditure | Energy Metabolism | Body FluidsUnited States
-
Wageningen UniversityRecruiting
-
Universidad de GranadaRecruiting
-
Abbott NutritionCompletedEnergy MetabolismUnited States
-
University of FloridaOsato Research InstituteCompleted
-
Maastricht University Medical CenterMinistry of Economic AffairsCompletedAlgorithms | Energy MetabolismNetherlands
-
Pennington Biomedical Research CenterOmniActive Health TechnologiesCompletedEating | Hunger | Energy MetabolismUnited States
-
University of GuelphMcMaster University; Medical University of BialystokUnknownSkeletal Muscle Energy MetabolismCanada
Clinical Trials on Intervallic submaximal exercise test
-
University of Rennes 2RecruitingHealthy Young Women | Healthy Young MenFrance
-
University of Rennes 2NahibuCompletedSedentary Behavior | Elite Cyclists | Elite Soccer PlayersFrance
-
Mayo ClinicCompleted
-
Georgetown UniversityCompletedChronic Fatigue Syndrome
-
University of Nevada, Las VegasRecruitingDown SyndromeUnited States
-
Marquette UniversityRecruitingHealthy SubjectsUnited States
-
Towson UniversityCompletedEndothelial Dysfunction | Arterial StiffnessUnited States
-
VA Office of Research and DevelopmentCompleted
-
Nanyang Technological UniversityMinistry of Education, SingaporeCompletedOverweight and ObesitySingapore